MDMB-FUBINACA

MDMB-FUBINACA.svg

MDMB-FUBINACA is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the cannabinoid receptors, specifically the CB1 receptor and CB2 receptor. MDMB-FUBINACA is structurally related to other synthetic cannabinoids such as AB-FUBINACA and ADB-FUBINACA.

Chemical Structure and Properties

MDMB-FUBINACA belongs to the indazole-3-carboxamide family of synthetic cannabinoids. Its chemical name is methyl (S)-2-[[1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate. The molecular formula is C21H29FN2O3, and it has a molecular weight of 376.47 g/mol.

Pharmacology

MDMB-FUBINACA acts as a potent agonist at the CB1 and CB2 receptors, which are part of the endocannabinoid system. These receptors are involved in various physiological processes including pain sensation, mood, and memory. The activation of these receptors by MDMB-FUBINACA can lead to psychoactive effects similar to those produced by tetrahydrocannabinol (THC), the active component of cannabis.

Usage and Effects

MDMB-FUBINACA has been found in various synthetic cannabis products, often marketed under names like "spice" or "K2". Users may experience effects such as euphoria, relaxation, altered perception, and in some cases, adverse effects like anxiety, paranoia, and hallucinations. Due to its potency, the risk of overdose and severe side effects is higher compared to natural cannabis.

Legal Status

The legal status of MDMB-FUBINACA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. For example, in the United States, it is listed as a Schedule I substance under the Controlled Substances Act.

Health Risks and Toxicity

The use of MDMB-FUBINACA has been associated with numerous adverse health effects, including acute intoxication, cardiovascular issues, and in severe cases, death. The lack of regulation and quality control in the production of synthetic cannabinoids further increases the risk of harmful effects.

Detection in Biological Samples

MDMB-FUBINACA can be detected in biological samples using various analytical techniques such as gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS). These methods are used in forensic and clinical toxicology to confirm exposure to the substance.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system
• Controlled Substances Act

External Links

‎